We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing ... Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. Show more
Kuehn Law Encourages INFN, RPHM, VAPO, and PRFT Investors to Contact Law Firm PR Newswire NEW YORK, July 1, 2024 NEW YORK, July 1, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKureโs portfolio of novel precision medicines in oncology Combined company is expected to have...
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies...
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies...
Period โ | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -9.43396226415 | 1.59 | 1.65 | 1.48 | 118310 | 1.55823783 | CS |
4 | -0.24 | -14.2857142857 | 1.68 | 1.93 | 1.48 | 135468 | 1.63983901 | CS |
12 | -0.24 | -14.2857142857 | 1.68 | 1.93 | 1.42 | 264802 | 1.64379483 | CS |
26 | -0.22 | -13.2530120482 | 1.66 | 1.93 | 1.32 | 276654 | 1.64825064 | CS |
52 | -5.91 | -80.4081632653 | 7.35 | 9.21 | 0.9801 | 416512 | 2.59450249 | CS |
156 | -8.06 | -84.8421052632 | 9.5 | 11.3999 | 0.9801 | 183680 | 3.39088289 | CS |
260 | -13.86 | -90.5882352941 | 15.3 | 16.83 | 0.9801 | 177972 | 3.74787936 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions